Kymera Q2 revenue rises to $65.0 million; net loss narrows to $61.2 million
Kymera Therapeutics reported second-quarter 2026 results, with collaboration revenue of $65.0 million, up from $11.5 million a year earlier, mainly from a $45 million Gilead option fee and a $20 million Sanofi milestone. The net loss narrowed to $61.2 million from $76.6 million, though research and development spending rose to $119.5 million from $78.4 million. The company said enrollment in its KT-621 atopic dermatitis Phase 2b trial finished nearly six months early, moving topline data to year-end 2026, and that cash was $1.5 billion as of June 30, 2026.
Key points
- Collaboration revenue was $65.0 million, versus $11.5 million in Q2 2025, including a $45 million Gilead option fee and a $20 million Sanofi milestone.
- Net loss was $61.2 million, or $0.62 per share, versus $76.6 million, or $0.95 per share, a year earlier.
- Research and development expenses rose to $119.5 million from $78.4 million.
- KT-621 BROADEN2 atopic dermatitis topline data are now expected by year-end 2026, six months earlier than prior guidance of mid-2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.